We designed the Framework to create significant value for shareholders by focusing our portfolio and leveraging our financial strength.
The increase in both periods was led by the Optical Communications segment, which increased $200 million and $409 million, respectively, due to higher sales of carrier network products in North America and Europe, an increase in sales of enterprise network products from growth in data centers and sales from 3M’s Communications Market Division which we acquired in June.
Net sales in the Display Technologies segment increased by $57 million and $23 million, respectively, for the three and nine months ended September 30, 2018, with volumes exceeding the display glass market’s strong growth and more than offsetting price declines.
Life Sciences sales increased by $8 million and $54 million, respectively, driven by higher sales across all product lines.
·    Lower segment net income in the All Other segment, down $8 million, resulting from continued investment in product development.
Diluted earnings per share increased by $0.28 per share, or 72%, when compared to the third quarter of 2017, driven by the increase in net income described above, coupled with the repurchase of 76 million shares of common stock over the last twelve months.
·    An increase in the translated earnings contract gains of $174 million.
Diluted earnings per share decreased by $0.07 per share, or 8%, when compared to the nine months ended September 30, 2017, driven by the decrease in net income described above, coupled with the repurchase of 76 million shares of common stock over the last twelve months.
In our Display Technologies segment, we expect pricing to continue to improve, with moderate year-over-year declines during the fourth quarter, an important milestone toward our goal of stabilizing returns.
For the full year, we anticipate Corning’s glass volume will grow faster than the expected display glass market growth of mid-single digits, driven by the ramp of our Gen 10.5 facility in China.
We expect organic growth will improve by a low-teen percentage range driven by strong demand from carrier and enterprise network customers.
We expect mid-to-high single digit percentage growth in the Life Sciences segment.
In the three and nine months ended September 30, 2018, gross margin increased by $182 million, or 17%, and $271 million, or 9%, respectively, primarily driven by an increase in sales across all operating segments.
Gross margin as a percentage of net sales increased by 1% for the three months ended September 30, 2018.
As a percentage of sales, these expenses were flat when compared to the same period last year.
For the nine months ended September 30, 2018, research, development and engineering expenses increased by $105 million, or 17%, when compared to the same period last year, driven by higher costs associated with new product launches and our emerging businesses.See our 2017 Form 10-K, Part I, Item 3.